Webcast 4 2020 Quarterly Results PDF Release AUDIO Webcast PDF HTML 10-K Filing ZIP XLS HTML XBRL
Fourth Quarter 2020 Operational Highlights and Financial Results Conference Call Read More »
IRB Approval Signals Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients May Proceed as Planned; Enrollment Anticipated to Commence During Q1 2021 ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet
— Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients May Proceed as Planned; Trial Commencement Anticipated in Q1 2021 — — Received Study-May-Proceed Letter from the FDA Supporting a Phase 1 Single Ascending Dose Study of SYN-020 IAP; Phase 1 Study to Support Development of
2 2020 Quarterly Results PDF Release PDF HTML 10-Q Filing ZIP XLS HTML XBRL
Second Quarter 2020 Operational Highlights and Financial Results Conference Call Read More »
— Company Updates Guidance and Clinical Development Timeline in Response to the COVID-19 Global Pandemic — — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md., May 5, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas
— Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 — — Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md.,
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results Read More »
ROCKVILLE, Md., Jan. 7, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the receipt of official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C
— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 4, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent
— Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Conference Call Today, August 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company
— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 — — Conference Call Today, May 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., May 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that
